Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
09. Juni 2020 08:00 ET
|
Vaccinex, Inc.
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease
09. Dezember 2019 07:55 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program
14. November 2019 07:55 ET
|
Vaccinex, Inc.
Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ...
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
14. August 2019 08:30 ET
|
Vaccinex, Inc.
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data...
Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer
13. August 2019 08:05 ET
|
Vaccinex, Inc.
63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated...
Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
26. Oktober 2017 10:23 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
24. April 2017 10:28 ET
|
Vaccinex, Inc.
- Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...
Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial
09. September 2016 09:45 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
23. August 2016 10:15 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington's Disease (the SIGNAL Trial)
24. Juni 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 24, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D...